Taysha Gene Therapies, Inc.
TSHA
$3.27
$0.113.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.86% | -14.61% | 26.40% | -21.96% | 13.02% |
| Total Depreciation and Amortization | -2.12% | -6.91% | 3.40% | -8.70% | -0.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.97% | 36.34% | -70.79% | 180.64% | -7.03% |
| Change in Net Operating Assets | 148.86% | -75.16% | 55.78% | -37.37% | -1,536.91% |
| Cash from Operations | 8.35% | -20.28% | 15.30% | -0.52% | -8.62% |
| Capital Expenditure | 99.47% | -19,000.00% | 105.71% | 82.59% | -43.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 814.29% | -36.36% | -- | -- | -- |
| Cash from Investing | 116.71% | -2,953.85% | 137.14% | 82.59% | -43.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 288,126.67% | -- | -- | -90.46% | 270,980.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 192.91% | -4,333.33% | 102.36% | -876.92% | 72.92% |
| Cash from Financing | 416,038.46% | 85.43% | -105.41% | -90.64% | 320,409.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 974.07% | -20.32% | -23.89% | -130.87% | 344.30% |